References
- Garratty G. Immune hemolytic anemia associated with drug therapy. Blood Rev. 2010;24(4–5):143–150. doi: 10.1016/j.blre.2010.06.004
- Garratty G. Immune hemolytic anemia caused by drugs. Expert Opin Drug Saf. 2012;11(4):635–642. doi: 10.1517/14740338.2012.678832
- Leger RM, Arndt PA, Garratty G. How we investigate drug-induced immune hemolytic anemia. Immunohematology. 2014;30(2):85–94. PMID: 25247618 doi: 10.21307/immunohematology-2019-102
- Hill QA, Stamps R, Massey E, et al. British Society for Haematology Guidelines. Guidelines on the management of drug-induced immune and secondary autoimmune, haemolytic anaemia. Br J Haematol. 2017 Apr;177(2):208–220. doi: 10.1111/bjh.14654
- Tanios GE, Doley PB, Munker R. Autoimmune hemolytic anemia associated with the use of immune checkpoint inhibitors for cancer: 68 cases from the food and drug administration database and review. Eur J Haematol. 2019;102(2):157–162. doi: 10.1111/ejh.13187
- Fattizzo B, Barcellini W. Autoimmune hemolytic anemia: causes and consequences. Expert Rev Clin Immunol. 2022;18(7):731–745. doi: 10.1080/1744666X.2022.2089115
- Schubert ML, Schmitt M, Wang L, et al. Side-effect management of chimeric antigen receptor (CAR) T-cell therapy. Ann Oncol. 2021;32(1):34–48.
- Feng CC, Chang CW, Lien ZY, et al. Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test. J Clin Lab Anal. 2023;37(8):e24891.
- Ahrens N, Genth R, Kiesewetter H, et al. Misdiagnosis in patients with diclofenac-induced hemolysis: new cases and a concise review. Am J Hematol. 2006;81:128–131. doi: 10.1002/ajh.20494
- Garbe E, Andersohn F, Bronder E, et al. Drug induced immune haemolytic anaemia in the Berlin case–control surveillance study. Br J Haematol. 2011;154:644–653. doi: 10.1111/j.1365-2141.2011.08784.x
- Leaf RK, Ferreri C, Rangachari D, et al. Clinical and laboratory features of autoimmune hemolytic anemia associated with immune checkpoint inhibitors. Am J Hematol. 2019;94(5):563–574.
- Yunce M, Katyal N, Monis GF, et al. Neonatal Fc receptor blockade as emerging therapy in diseases with plasma exchange indications. J Clin Apheresis. 2023;38(5):632–640.
- Bhandari V, Bril V. FcRN receptor antagonists in the management of myasthenia gravis. Front Neurol. 2023;14:1229112. doi: 10.3389/fneur.2023.1229112
- Broome CM, McDonald V, Miyakawa Y, et al. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2023;S0140-6736(23):01460–5.
- Bortolotti M, Barcellini W, Fattizzo B. Molecular pharmacology in complement-mediated hemolytic disorders. Eur J Haematol. 2023;111(3):326–336. doi: 10.1111/ejh.14026